Home
News & Events
News
117
Results found
-
RSNN Annual Report 2025
In 2025, RSNN celebrated its 10-year anniversary. In the Annual Report, we are presenting an overview of the activities and achievements of RSNN in 2025. -
RSNN Expert Meeting Report โ Potential of the EPND to aid biomarker discovery and validation
On Thursday 11 September 2025, a Regulatory Science Network Netherlands (RSNN) Expert Meeting was held with a total of twenty-six participants with diverse expertise from nine different European countries. During the meeting the potential of the European Platform for Neurodegenerative Diseases (EPND) was discussed. -
Advancing Regulatory Science and New Approach Methodologies: Key Insights from the 2025 Expert Meeting
On December 9th, the masterclass ๐๐ฟ๐ถ๐ฑ๐ด๐ถ๐ป๐ด ๐๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป ๐ฎ๐ป๐ฑ ๐ฅ๐ฒ๐ด๐๐น๐ฎ๐๐ถ๐ผ๐ป โ ๐ง๐ต๐ฒ ๐ก๐๐ ๐ ๐๐ต๐ฎ๐น๐น๐ฒ๐ป๐ด๐ฒ on New Approach Methodologies (NAMs) brought together scientists, regulators, industry leaders and innovation networks to discuss how scientific advances can accelerate safer, more effective, and increasingly animal-free drug development. -
2025 RSNN Annual Workshop Report available now
The full report of the RSNN Annual Workshop titled "Single Arm Trialsโ, which took place on 18 November 2025 is now available. -
A decade of RSNN: an interview with four RSNN pioneers
In 2025, the Regulatory Science Network Netherlands (RSNN) marked its ten-year anniversary. -
RSNN Annual Workshop 2025: presentations and photos are now available
On November 18th, RSNN celebrated its 10 year anniversary during the Annual Workshop. The Annual Workshop focused on Single Arm Trials with its benefits and challenges. -
RSNN SIG Expert Meeting Report - In vivo gene editing
The RSNN Special Interest Group Advanced Therapies Expert Meeting on in vivo gene editing took place on Tuesday 15 July 2025. -
RSNN at FIGON Dutch Medicines Day: Presentations now available
On 9 October RSNN organized a parallel session at the FIGON Dutch Medicines Days on the topic "Patient Access to Unregistered Medicines: Current Developments in Compassionate Use" (Abstract). The slides presented during this session are now available for download. -
Introducing the new co-chair of RSNN: Rick Vreman
As of 2025, Rick Vreman (Policy Lead and Head of Access Operations at Roche Netherlands) has been appointed as co-chair of the RSNN. He is replacing Sjaak Bot, who retired last year, as representative of the industry stakeholder group. We spoke with Rick about his background, the RSNN, and his new position. -
RSNN Expert Meeting Rapport - Klinisch onderzoeksklimaat in Nederland: Reflectie en vooruitblik op het Nationaal Actieplan Klinisch Onderzoek
Op woensdag 12 maart 2025 vond de opvolgende RSNN Expert meeting โKlinisch onderzoeksklimaat in Nederland: Reflectie en vooruitblik op het Nationaal Actieplan Klinisch Onderzoekโ plaats. Een groep van 26 experts kwam bijeen om te reflecteren op het Nationaal Actieplan Klinisch Onderzoek. -
Register now for the RSNN Annual Workshop 2025!
Registration for the RSNN Annual Workshop 2025: "One arm, many challenges: the role of single-arm trials in regulatory and clinical context" is now open. The event will take place on 18 November 2025 in person at Villa Jongerius in Utrecht. -
Report of the RSNN SIG Advanced Therapies and FAST workshop now available
โParticipants of the multistakeholder workshop expressed a clear need for a national ATMP network.โ -
10 years RSNN: jointly shaping regulatory innovation
We are excited to announce that 2025 will mark the 10 year anniversary of the RSNN! Over the past 10 years the RSNN has successfully brought relevant stakeholders together around important regulatory topics, and has contributed to setting the agenda for regulatory innovation in the Netherlands and internationally. -
RSNN Expert Meeting Report - Minimal Dataset for Non-Small Cell Lung Cancer (NSCLC) Registry
The RSNN Expert Meeting on the topic of a minimal dataset for Non-Small Cell Lung Cancer (NSCLC) registry took place on 25 September 2024. The aim of the meeting was to gather input on the concept NSCLC minimal dataset. 15 experts representing various backgrounds such as regulators, HTA experts and patient representatives attended the meeting. -
Article published in Drug Discovery Today: Learning from European regulator-initiated studies for regulatory decision making
"Future meetings, discussions and workshops within, but not limited to, the European regulatory network are recommended to establish publicly disclosed interaction models to facilitate interaction between stakeholders (...) with the goal of realising an optimal framework for generating RWE to be included in the regulatory decision-making process."